UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14C INFORMATION
___________________________
Definitive
Information Statement Pursuant to Section 14(c)
of
the Securities Exchange Act of 1934
___________________________
Check
the appropriate box:
o
Preliminary Information Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
x
Definitive Information Statement
ONCOLOGIX
TECH, INC.
(
Name
of Registrant Specified in Charter
)
Payment
of filing fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rule 14c-5(g) and 0-11
|
(1)
|
|
Title
of each class of securities to which transaction applies: N/A
|
|
(2)
|
|
Aggregate
number of securities to which transactions applies: N/A
|
|
(3)
|
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it
was determined): N/A
|
|
(4)
|
|
Proposed
maximum aggregate value of transaction: N/A
|
o
Fee paid previously with preliminary materials
o
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of
its filing.
|
(1)
|
|
Amount
previously paid: $0
|
|
(2)
|
|
Form,
schedule or registration statement no.: N/A
|
ONCOLOGIX
TECH, INC.
P.O.
Box 8832
Grand
Rapids, MI 49518-8832
(616)
977-9933
Fax:
(616) 977-9955
INFORMATION
STATEMENT
WE
ARE NOT ASKING YOU FOR A PROXY AND YOU ARE
REQUESTED
NOT TO SEND A PROXY
Dear
Shareholders:
We
are writing to advise you that our Board of Directors and shareholders holding a majority of our outstanding voting capital stock
have approved an amendment to the articles of incorporation (the "Amendment") to increase the total authorized common
stock from 200 million shares of common stock, par value $0.001, to 750 million shares of common stock (the "Increase in
Common Stock") and to approve the 2013 Omnibus Incentive Plan.
Oncologix
Tech, Inc. obtained the written consents representing 56.30% of the Company’s voting power on January 27, 2014 approving
the above-mentioned corporate actions. Pursuant to Rule 14C-2 under the Securities Exchange Act of 1934, as amended, the actions
will not be effective and any required state filings effectuating the corporate actions will not be filed with the Secretary of
State for the State of Nevada until twenty (20) days after the date of a Definitive Information Statement is filed with the Securities
and Exchange Commission and a copy thereof is mailed to each of the Company’s stockholders.
WE
ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
No
action is required by you. The accompanying information statement is furnished only to inform our stockholders of the actions
described above before they take place in accordance with the requirements of United States federal securities laws. This Information
Statement is being mailed on or about February 10, 2014 to all stockholders of record as of the close of business on January 30th,
2014. Pursuant to Rule 14(c)-2 under the Securities Exchange Act of 1934, as amended, the proposals will not be adopted until
a date at least twenty (20) days after the date of this Information Statement has been mailed to our shareholders. This Information
Statement is first mailed to you on or about February 10, 2014, to shareholders of record on January 30, 2014.
Description
of Amendment to Article 4 of the Articles of Incorporation.
The
Company’s Articles of Incorporation are amended to increase the number of authorized shares of the Company’s Common
Stock from 200,000,000 to 750,000,000. The first paragraph of Article 4 of the Company’s Articles of Incorporation is to
be deleted in its entirety and amended so as to read as follows:
|
4.
|
|
“The
authorized capital stock of this corporation shall be seven hundred fifty million (750,000,000)
shares of common stock, $.001 par value, and ten million (10,000,000) shares of preferred
stock, $.001 par value.
|
The
proposed Certificate of Amendment is attached hereto as Exhibit A.
We
believe it is necessary to authorize an additional 550,000,000 shares of common stock for sufficient future fund raising needs.
Currently we estimate that we will need $1,500,000 in funds for the next year of operations. The purpose of this proposed increase
in authorized common stock is to make available additional shares of common stock for issuance in subsequent financing activities,
acquisitions and other corporate purposes, without the requirement of further action by the shareholders of the Company. More
specifically, the Company expects to use some of the newly authorized shares of common stock as follows:
1)Secure
additional long-term financing to continue the Company’s new technology development in medical device and to place that
technology into production in the second quarter of 2014;
2)Enter
into strategic acquisitions of entities that can assist the Company in furthering its personal care services segment to provide
additional revenue resources; and
3)Eliminate
a substantial portion of debt and payables currently on the Company’s balance sheet, much of which is anticipated to be
converted to shares of common stock at above-market prices as of the respective dates of conversion.
Adoption
of the 2013 Omnibus Incentive Plan
Purposes
of the 2013 Omnibus Incentive Plan
The
purpose of the 2013 Stock Option Plan is to further our growth and financial success by providing additional incentives to selected
employees, directors and consultants of us and our Affiliates (referred to collectively as "Eligible Persons") by providing
incentives for Eligible Persons to exert maximum efforts for the success of us and our Affiliates. For the complete version of
our 2013 Omnibus Incentive Plan, please review our registration statement on Form S-8, which was filed with the Securities Exchange
Commission on May 28, 2013.
|
Date:
February 7, 2014
|
Oncologix, Inc.
|
|
|
By
|
/s/
Roy Wayne Erwin
|
|
|
|
Name: Roy Wayne Erwin
Title: Chief Executive Officer
|
ONCOLOGIX
TECH, INC.
PO
Box 8832
Grand
Rapids, MI 49518
INFORMATION
STATEMENT REGARDING
ACTION
TO BE TAKEN BY WRITTEN CONSENT OF
MAJORITY
SHAREHOLDERS
IN
LIEU OF A SPECIAL MEETING
PURSUANT
TO SECTION 14(C) OF THE
SECURITIES
EXCHANGE ACT OF 1934
WE
ARE NOT ASKING YOU FOR A PROXY,
AND
YOU ARE REQUESTED NOT TO SEND US A PROXY
GENERAL
This
Information Statement is being furnished to all holders of the common stock of Oncologix Tech, Inc. (the "Company")
as of January 30, 2014 in connection with the action taken by written consent of holders of a majority of the outstanding voting
power of the Company to authorize the Amendment and the Increase in Common Shares and to approve the 2013 Omnibus Incentive Plan.
"We,"
"us," "our," the “Registrant” and the "Company" refers to Oncologix Tech, Inc., a Nevada
corporation.
SUMMARY
OF CORPORATE ACTIONS
ITEM
1
INFORMATION
STATEMENT
This
Information Statement is furnished to the stockholders of the Company in connection with our prior receipt of approval by written
consents, in lieu of a special meeting, of the holders of a majority of our outstanding voting power authorizing the Board of
Directors of the Company to amend the articles of incorporation of the Company (the "Amendment") to effectuate an increase
in the authorized common stock from 200 million shares of common stock to 750 million shares of common stock (the "Increase
in Common Stock"). On January 30, 2014, the Company obtained the approval of the Amendment and the Increase in Common
Stock by written consent of the stockholders, which by virtue of the Company’s Articles of Incorporation and Certificate
of Designation, have the power to vote 56.30% of the common shares of the Company in all matters brought before the shareholders.
Furthermore, the company obtained the approval of our 2013 Omnibus Incentive Plan.
The
Amendment and the Increase in Common Stock cannot be effectuated until twenty (20) days after the mailing of this Information
Statement and after the filing of the amended Articles of Incorporation with Secretary of State of the State of Nevada with respect
to the Amendment and the Increase in Common Stock. The amendment to the Articles of Incorporation is to effectuate the Increase
in Common Stock.
The
date on which this Information Statement will be sent to stockholders will be on or about February 10, 2014 and is being furnished
to all holders of the common stock of the Company on record as of January 30, 2014.
The
Board of Directors, and persons owning a majority of the outstanding voting securities of the Company have unanimously adopted,
ratified and approved the proposed actions by the Company's board of directors. No other votes are required or necessary.
The
Annual Report on Form 10-K for fiscal year ended August 31, 2013 and the Quarterly Reports on Form 10-Q for the quarter ended
November 30, 2013, and the Current Reports on Form 8-K filed by the Company during the past year with the Securities and Exchange
Commission may be viewed on the Securities and Exchange Commission’s web site at
www.sec.gov
in the Edgar Archives.
The Company is presently current in the filing of all reports required to be filed by it.
Only
one information statement is being delivered to multiple shareholders sharing an address, unless we have received contrary instructions
from one or more of the shareholders. We will undertake to deliver promptly upon written or oral request a separate copy of the
information statement to a stockholder at a shared address to which a single copy of the information statement was delivered.
You may make a written or oral request by sending a written notification to our principal executive offices stating your name,
your shared address, and the address to which we should direct the additional copy of the information statement or by calling
our principal executive offices at (616) 977-9933. If multiple shareholders sharing an address have received one copy of this
information statement and would prefer us to mail each stockholder a separate copy of future mailings, you may send notification
to or call our principal executive offices. Additionally, if current shareholders with a shared address received multiple copies
of this information statement and would prefer us to mail one copy of future mailings to shareholders at the shared address, notification
of that request may also be made by mail or telephone call to our principal executive offices.
VOTE
REQUIRED
Pursuant
to the Company's Bylaws and the Nevada Corporations Law, a vote by the holders of at least a majority of the Company’s outstanding
votes is required to effect the Amendment and the Increase in Common Stock and to approve the 2013 Omnibus Incentive Plan. The
Company’s Articles of Incorporation does not authorize cumulative voting. As of January 27, 2014, the Company had 94,172,904
voting shares of common stock issued and outstanding and 23,425,600 votes represented by shares of Series D Convertible Preferred
Stock issued and outstanding.
PROPOSAL
1
AMENDMENT
TO OUR ARTICLES OF INCORPORATION
TO
INCREASE THE COMMON STOCK OF THE CORPORATION
Purpose
and Effect of Amendment
On
January 27, 2014, our Board of Directors and a majority of the voting power of our common and preferred stock shareholders, believing
it to be in the best interests of the Company and its shareholders, approved the amendment to the Company's Articles to increase
the authorized common stock of the Company from 200 million shares of common stock to 750 million shares of common stock.
The
purpose of this proposed increase in authorized common stock is to make available additional shares of common stock for issuance
in subsequent financing activities, acquisitions and other corporate purposes, without the requirement of further action by the
shareholders of the Company. More specifically, the Company expects to use some of the newly authorized shares of common
stock as follows:
1)Secure
additional long-term financing to continue the Company’s new technology development in medical device and to place that
technology into production in the second quarter of 2014;
2)Enter
into strategic acquisitions of entities that can assist the Company in furthering its personal care services segment to provide
additional revenue resources; and
3)Eliminate
a substantial portion of debt and payables currently on the Company’s balance sheet, much of which is anticipated to be
converted to shares of common stock at above-market prices as of the respective dates of conversion.
The
Company is investigating additional sources of financing and strategic acquisitions which the Board of Directors believes will
be in the best interests of our shareholders. We also seek to exchange indebtedness for stock to make our balance sheet more attractive
to investors, which management believes is necessary for our future growth and success. Increasing the authorized number
of shares of common stock of the Company will provide greater flexibility and allow the issuance of additional shares of common
stock in most these cases without the expense or delay of seeking further approval from the shareholders.
We
have no commitments or specific plans for any of the foregoing and no assurance is given that any of those events will occur.
As
of January 27, 2014, we had approximately 94 million shares of common stock issued and outstanding, 79 thousand shares of Series
D Convertible Preferred Stock exclusive of approximately 21 million warrants and options that could be exercised in the future,
and an estimated 1 million shares for the conversion of convertible note obligations.
The
shares of common stock do not carry any pre-emptive rights. The adoption of the Amendment will not of itself cause any changes
in the Company's capital accounts.
The
increase in authorized common stock will not have any immediate effect on the rights of existing shareholders. However, the Board
of Directors will have the authority to issue authorized shares of common stock without requiring future approval from the shareholders
of such issuances, except as may be required by applicable law or exchange regulations. To the extent that additional authorized
shares of common stock are issued in the future, they will decrease the existing shareholders' percentage equity ownership interests
and, depending upon the price at which such shares of common stock are issued, could be dilutive to the existing shareholders.
Any such issuance of additional shares of common stock could have the effect of diluting the earnings per share and book value
per share of outstanding shares of common stock of the Company.
One
of the effects of the increase in authorized common stock, if adopted, however, may be to enable the Board of Directors to render
it more difficult to or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest
or otherwise, and thereby protect the continuity of present management. The Board of Directors would, unless prohibited by applicable
law, have additional shares of common stock available to effect transactions (including private placements) in which the number
of the Company's outstanding shares would be increased and would thereby dilute the interest of any party attempting to gain control
of the Company. Such action could discourage an acquisition of the Company which the shareholders of the Company might view as
desirable. The Board of Directors has no current intention of using the newly authorized shares for this purpose.
Effective
Time of the Amendment
We
intend to file, as soon as practicable on or after the 20th day after this Information Statement is sent to our shareholders,
an amendment to our Articles of Incorporation effectuating the Increase in Common Stock with the Secretary of State of Nevada.
The Amendment to our Articles of Incorporation will become effective at the close of business on the date the Certificate of Amendment
to the Articles of Incorporation is accepted for filing by the Secretary of State of Nevada. It is presently contemplated that
such filing will be made approximately twenty (20) days from the date that this Information Statement is sent to our shareholders.
The text of the Certificate of Amendment to the Articles of Incorporation is subject to modification to include such changes as
may be required by the Nevada Secretary of State to effectuate the Amendment.
No
Appraisal Rights for the Amendment
Under
Nevada law, the Company’s shareholders are not entitled to appraisal rights with respect to the Authorized Common Stock
Amendment and the Company will not independently provide shareholders with any such right.
PROPOSAL
2
APPROVAL
OF 2013 OMNIBUS INCENTIVE PLAN
Description
and Purpose of the Plan
Oncologix
Tech, Inc. ., a Nevada corporation (the “Company”), desires to establish several types of incentive plans in one plan
thus giving it the flexibility to reward and incentivize employees, officers, directors and consultants in various manners. Rather
than establishing several plans, the Company is establishing this Oncologix Tech, Inc. 2013 Omnibus Incentive Plan (the “Plan”).
The
purpose of the Plan is to aid the Company in attracting, retaining, motivating and rewarding employees, Non-Employee Directors,
and other persons who provide substantial services to the Company or its Affiliates, to provide for equitable and competitive
compensation opportunities, including deferral opportunities, to encourage long-term service, to recognize individual contributions
and reward achievement of Company goals, and promote the creation of long-term value for shareholders by closely aligning the
interests of Participants with those of shareholders. The Plan authorizes stock-based and cash-based incentives for Participants.
For the complete version of our 2013 Omnibus Incentive Plan, please review our registration statement on Form S-8, which was filed
with the Securities Exchange Commission on May 28, 2013.
BOARD
OF DIRECTORS’ RECOMMENDATION
AND
STOCKHOLDER APPROVAL
On
January 27, 2014, our Board of Directors voted to authorize and seek approval of our shareholders of an amendment to our Articles
of Incorporation to effect the Increase in Common Stock. In the absence of a meeting, the affirmative consent of holders was required
to approve the Increase in Common Stock of the Company. Because holders of all shares of common and preferred stock signed
a written consent in favor of the amendment to the Articles of Incorporation, we are authorized to amend the Articles of Incorporation
to effect the Increase in Common Stock. The Amendment and the Increase in Common Stock will be effective upon the filing of an
amendment to the Articles of Incorporation with the Secretary of State of the State of Nevada, which is expected to occur as soon
as reasonably practicable on or after the 20th day following the mailing of this Information Statement to stockholders.
The
information contained in this information statement constitutes the only notice we will be providing stockholders.
QUESTIONS
AND ANSWERS REGARDING
THE
PROPOSED INCREASE IN COMMON STOCK
Q.
HAS THE BOARD OF DIRECTORS APPROVED THE PROPOSALS TO AFFECT THE PROPOSED INCREASE IN COMMON STOCK?
A.
All members of the Board of Directors have approved the proposal to authorize the board to effectuate the Increase in Common Stock
as is in the best interests of the Company and the best interests of the current shareholders of the Company.
Q.
WHAT VOTE OF THE SHAREHOLDERS WILL RESULT IN THE PROPOSAL BEING PASSED?
A.
To approve the proposal the affirmative vote of a majority of the potential votes cast as stock holders is required. Consents
in favor of the proposal have already been received from shareholders holding a majority of the voting power of the Company.
Q.
WHAT WILL I RECEIVE IF THE AMENDMENT IS COMPLETED?
A.
The Amendment will only modify the Articles of Incorporation.
Q.
WHEN DO YOU EXPECT THE AMENDMENT TO BECOME EFFECTIVE?
A.
The Amendment will become effective upon the filing of the Amendment with the Secretary of State of Nevada. We expect to file
the Amendment with the Secretary of State of Nevada no less than 20 days after this Information Statement has been sent to you.
Q.
WHY AM I NOT BEING ASKED TO VOTE?
A.
The holders of a majority of the issued and outstanding shares of our voting stock have already approved the Amendment pursuant
to a written consent in lieu of a meeting. Such approval, together with the approval of the Company's Board of Directors, is sufficient
under Nevada law, and no further approval by our shareholders is required.
Q.
WHAT DO I NEED TO DO NOW?
A.
You do not need to do anything. This Information Statement is purely for your information and does not require or request you
to do anything.
Q.
WHO IS PAYING FOR THIS INFORMATION STATEMENT?
A.
The Company will pay for the delivery of this Information Statement.
Q.
WHOM SHOULD I CONTACT IF I HAVE ADDITIONAL QUESTIONS?
A:
Roy Wayne Erwin, CEO and Chairman of the Company.
VOTE
REQUIRED FOR APPROVAL
In
accordance with the Nevada Corporations Law, the following actions were taken based upon the unanimous recommendation and approval
by the Company's Board of Directors and the written consent of the majority voting control of the shareholders.
The
Board of Directors of the Company has adopted, ratified and approved the Increase in Common Stock and the approval of the 2013
Omnibus Incentive Plan. The Company obtained the written consents representing 56.30% of the Company’s voting power on January
27, 2014 approving the above-mentioned corporate actions. Pursuant to Rule 14C-2 under the Securities Exchange Act of 1934, as
amended, the actions will not be effective and any required state filings effectuating the corporate actions will not be filed
with the Secretary of State for the State of Nevada until twenty (20) days after the date of a Definitive Information Statement
is filed with the Securities and Exchange Commission and a copy thereof is mailed to each of the Company’s stockholders.
VOTING
SECURITIES AND PRINCIPAL HOLDERS THEREOF
The
Board of Directors fixed the close of business on January 30, 2014 as the record date for the determination of holders of our
common stock to receive this Information Statement.
At
the record date, the Company had 200 million shares of common stock authorized with a stated par value of $0.001, of which approximately
94 million shares of common stock were issued and outstanding, excluding warrants, options and shares estimated for the conversion
of notes. The holders of shares of common stock are entitled to one vote per share on matters to be voted upon by shareholders.
The
holders of shares of common stock are entitled to receive pro rata dividends, when and if declared by the Board of Directors in
its discretion, out of funds legally available therefore, but only if dividends on preferred stock have been paid in accordance
with the terms of the outstanding preferred stock and there exists no deficiency in the sinking fund for the preferred stock.
Dividends
on the common stock are declared by the Board of Directors. Payment of dividends on the common stock in the future, if any, will
be subordinate to the preferred stock (if provided in the stock’s Certificate of Designation), must comply with the provisions
of the Nevada Corporations Law and will be determined by the Board of Directors. In addition, the payment of any such dividends
will depend on the Company's financial condition, results of operations, capital requirements and such other factors as the Board
of Directors deems relevant.
SECURITY
OWNERSHIP OF EXECUTIVE OFFICERS, DIRECTORS
AND
FIVE PERCENT STOCKHOLDERS
The
following table sets forth certain information concerning the ownership of the Company's common stock as of January 30, 2014 with
respect to: (i) each person known to the Company to be the beneficial owner of more than five percent of the Company's common
stock; (ii) all directors and executive officers; and (iii) directors and executive officers of the Company as a group. The notes
accompanying the information in the table below are necessary for a complete understanding of the figures provided below. As of
January 30, 2014, there were 94,172,904 shares of common stock issued and outstanding.
The
following table sets forth as of January 30, 2014, certain information with regard to the beneficial ownership of our common stock
held by (i) each shareholder known by us to beneficially own 5% or more of our outstanding common stock, (ii) each director individually,
(iii) the named executive officers and (iv) all of our officers and directors as a group:
|
|
Name
and Address
|
Amount
and Nature
|
|
Percent
|
|
Title
of Class
|
of
Beneficial Owner (2)
|
of
Beneficial Owner (1)
|
|
of
Class (1)(3)
|
|
|
|
|
|
|
|
Common Stock
|
Roy Wayne Erwin
|
58,464,000
|
(4)
|
38.30%
|
|
|
|
|
|
|
|
Common Stock
|
Michael Kramarz
|
2,112,750
|
(5)
|
2.19%
|
|
|
|
|
|
|
|
Common Stock
|
Barry Griffith
|
225,000
|
(6)
|
0.24%
|
|
|
|
|
|
|
|
Common Stock
|
Vickie Hart
|
1,600,000
|
(7)
|
1.67%
|
|
|
|
|
|
|
|
Common Stock
|
Anthony Silverman
|
6,222,395
|
(8)
|
6.61%
|
|
|
7625 E Via Del Reposo
|
|
|
|
|
|
Scottsdale, AZ 85028
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
Donald Schreifels
|
26,318,570
|
(9)
|
25.89%
|
|
|
6900 Wedgewood Drive, #340
|
|
|
|
|
|
Minneapolis, MN 55311
|
|
|
|
|
|
|
|
|
|
|
|
All directors and executive officers as a group
|
|
|
|
|
Common Stock
|
(four persons)
|
62,401,750
|
|
39.90%
|
Less than 1%
|
(1)
|
|
Unless otherwise noted, the address of each holder is P.O. Box 8832, Grand Rapids,
MI 49518-8832.
|
|
(2)
|
|
A person is deemed to be the beneficial owner of securities that can be acquired within
60 days from January 30, 2014 through the exercise of any option, warrant or other right. Shares of Common Stock subject to options,
warrants or rights which are currently exercisable or exercisable within 60 days are deemed outstanding solely for computing the
percentage of the person holding such options, warrants or rights, but are not deemed outstanding for computing the percentage
of any other person.
|
|
(3)
|
|
The amounts and percentages in the table are based
upon
96,672,904
shares
of Common Stock outstanding as of November 8, 2013.
|
|
(4)
|
|
Includes 2,400,000 shares subject to vested options and an indirect interest in 56,064
shares of Series D Convertible Preferred Stock, each share convertible into 1,000 shares of the Company’s common stock and
are held by Clearview Medical LLC, .
|
|
(5)
|
|
Includes 2,112,750 shares subject to vested options.
|
|
(6)
|
|
Includes 25,000 shares subject to vested options, direct ownership of 200,000 shares
of stock underlying units held.
|
|
(7)
|
|
Includes 1,600,000 shares subject to vested options.
|
|
(8)
|
|
Includes 3,500 shares subject to vested options, direct ownership of 6,218,895 shares
|
|
(9)
|
|
Includes direct ownership of 18,818,750 shares of common stock and direct ownership
of 7,500,000 three-year warrants to purchase common stock.
|
INTEREST
OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON
No
director, executive officer, nominee for election as a director, associate of any director, executive officer or nominee or any
other person has any substantial interest, direct or indirect, by security holdings or otherwise, in the proposed increase in
the number of authorized shares of the Company's common stock or in any action covered by the related resolutions adopted by the
Board of Directors, which is not shared by all other stockholders. Certain directors and executive officers of the Company may
be issued shares provided in the Amendment to Increase the Common Stock in return for the elimination of their debt to the Company
and deferred salary. This conversion is anticipated to be effectuated at prices above the market price for the Company’s
common stock at the time of conversion.
FORWARD-LOOKING
STATEMENTS
This
information statement may contain certain “forward-looking” statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995 or by the U.S. Securities and Exchange Commission in its rules, regulations and releases) representing
our expectations or beliefs regarding our Company. These forward-looking statements include, but are not limited to, statements
concerning our operations, economic performance, financial condition, and prospects and opportunities. For this purpose, any statements
contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the
generality of the foregoing, words such as “may,” “will,” “expect,” “believe,”
“anticipate,” “intend,” “could,” “estimate,” “might,” or “continue”
or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. These
statements, by their nature, involve substantial risks and uncertainties, certain of which are beyond our control, and actual
results may differ materially depending on a variety of important factors, including factors discussed in this and other of our
filings with the U.S. Securities and Exchange Commission.
WHERE
YOU CAN FIND MORE INFORMATION
We
are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and in accordance
with the Securities Exchange Act, we file periodic reports, documents, and other information with the Securities and Exchange
Commission relating to our business, financial statements, and other matters. These reports and other information may be inspected
and are available for copying at the offices of the Securities and Exchange Commission, 100 F Street, N.E., Washington, DC 20549.
Our SEC filings are also available to the public on the SEC’s website at
http://www.sec.gov
.
WE ARE
NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY
. This information statement is for informational purposes
only. Please read this information statement carefully.
|
Date:
February 7, 2014
|
By order of the Board of
Directors
|
|
|
By
|
/s/
Roy Wayne Erwin
|
|
|
|
Name: Roy Wayne Erwin
Title: Chief Executive Officer
|
CERTIFICATE
OF AMENDMENT
TO
THE
ARTICLES
OF INCORPORATION
OF
ONCOLOGIX
TECH, INC.
Pursuant
to Section 78.385 and 78.390 of the Nevada Revised Statutes, the undersigned corporation, Oncologix Tech, Inc., a Nevada corporation,
submits the following Certificate of Amendment for filing:
|
1.
|
|
The name of the corporation
is Oncologix Tech, Inc.
|
|
2.
|
|
The first paragraph of Article
4 of the Company’s Articles of Incorporation is to be deleted in its entirety and amended so as to read as follows:
|
Article
4. The authorized capital stock of this corporation shall be seven hundred fifty million (750,000,000) shares of common stock,
$.001 par value per share (the “Common Stock”), and ten million (10,000,000) shares of preferred stock, $.001 par
value per share, (the “Preferred Stock”). Such shares of the corporation’s capital stock may be issued from
time to time for such consideration as may be fixed by the Board of Directors.
|
3.
|
|
The vote by which the shareholders
holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion
of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of
the Articles of Incorporation have voted in favor of the amendment is: 56.30%.
|
IN
WITNESS WHEREOF, Oncologix Tech, Inc., a Nevada corporation, has caused this Certificate of Amendment to be signed in its name
and on its behalf, on this ____ day of February, 2014.
|
Date:
February 7, 2014
|
Oncologix, Inc.
|
|
|
By
|
/s/
Roy Wayne Erwin
|
|
|
|
Name: Roy Wayne Erwin
Title: President & CEO
|
Grafico Azioni Oncologix Tech (CE) (USOTC:OCLG)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Oncologix Tech (CE) (USOTC:OCLG)
Storico
Da Gen 2024 a Gen 2025
